hiltonol
poli
ic
lc
potent
immunomodul
synthet
doublestrand
polyriboinosinicpolyribocytidyl
acid
poli
ic
stabil
polyllysin
carboxymethyl
cellulos
lc
hiltonol
test
efficaci
lethal
sarscovinfect
balbc
mous
model
hiltonol
mgkgday
intranas
rout
result
signific
surviv
benefit
administ
select
time
h
prior
challeng
lethal
dose
mouseadapt
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
balbc
mice
receiv
hiltonol
treatment
also
significantli
effect
protect
mice
weight
loss
due
infect
p
group
mice
dose
hiltonol
mgkg
intranas
instil
day
viru
exposur
second
dose
given
h
later
prophylact
hiltonol
treatment
mgkg
day
complet
protect
prevent
death
caus
signific
reduct
lung
hemorrhag
score
lung
weight
lung
viru
titer
hiltonol
also
effect
therapeut
give
h
post
viru
exposur
theinfect
mice
protect
death
hiltonol
administ
mgkgday
h
infect
data
suggest
hiltonol
treatment
sarscov
infect
mice
lead
substanti
prophylact
therapeut
effect
could
use
treatment
viru
diseas
caus
merscov
relat
coronaviru
properti
might
therapeut
advantag
hiltonol
consid
possibl
clinic
use
publish
elsevi
bv
sever
acut
respiratori
syndrom
coronaviru
sarscov
caus
agent
emerg
human
infecti
diseas
sever
acut
respiratori
syndrom
sar
ksiazek
et
al
peiri
et
al
rota
et
al
relat
middl
east
respiratori
syndrom
merscov
infect
either
viru
associ
high
morbid
mortal
due
high
morbid
mortal
sar
evolv
import
global
respiratori
diseas
even
situat
new
infect
sar
remain
potenti
major
health
hazard
reemerg
epidem
may
aris
seriou
consequ
pose
virul
emerg
pathogen
sarscov
merscov
popul
littl
immun
highlight
sar
outbreak
princip
contain
strategi
date
emphas
rapid
diagnosi
isol
infect
patient
extent
contact
patient
howev
spite
enorm
effect
fund
expend
agent
approv
treat
sarscov
merscov
sarscov
pose
seriou
threat
human
popul
still
repres
challeng
antivir
drug
develop
administr
groneberg
et
al
groneberg
et
al
thu
numer
type
agent
test
sarscov
vitro
vivo
notabl
shown
antibodi
sarscov
spike
protein
block
entri
viru
cell
sui
et
al
small
peptid
deriv
heptad
repeat
hr
region
sarscov
protein
shown
inhibit
sarscov
infect
interf
sarscov
fusion
target
cell
bosch
et
al
ho
et
al
addit
main
proteas
sarscov
essenti
replic
cycl
sarscov
key
target
develop
antisarscov
drug
barnard
kumaki
yang
et
al
anoth
approach
explor
treat
sarscov
infect
evalu
rna
speci
therapi
thu
antisens
ribonucl
acid
rna
rna
interfer
rnai
technolog
shown
potenti
treat
sever
diseas
includ
sarscov
infect
ahlquist
gibson
johnsonsaliba
jan
leonard
schaffer
use
sirna
inhibit
sarscov
infect
rhesu
macaqu
demonstr
sirna
effect
prophylact
therapeut
chang
et
al
anoth
approach
use
drug
combin
combin
ribavirin
corticosteroid
frequent
administ
antivir
therapi
use
sar
outbreak
booth
et
al
ho
et
al
peiri
et
al
tsang
et
al
tsui
et
al
howev
ribavirin
alon
nontox
concentr
found
littl
vitro
activ
sarscov
although
improv
clinic
outcom
report
among
sar
patient
receiv
earli
administr
kaletra
plu
ribavirin
corticosteroid
tsang
seto
sever
mous
model
vitro
ribavirin
even
found
enhanc
sarscov
infect
barnard
et
al
barnard
et
al
day
et
al
recent
data
demonstr
urtica
dioica
agglutinin
uda
treatment
sarscovinfect
mice
lead
substanti
therapeut
effect
protect
mice
death
weight
loss
result
infect
kumaki
et
al
class
natur
molecul
interferon
consid
first
line
defens
viral
infect
human
isaac
lindenmann
isaac
et
al
earlier
studi
evalu
compound
approv
therapeut
use
human
vitro
inhibitor
sarscov
inhibit
mous
sarscov
replic
model
barnard
et
al
hybrid
interferon
interferon
alpha
ifna
bd
mismatch
doublestrand
ds
rna
interferon
induc
ampligen
poli
poli
shown
potent
inhibit
viru
titer
lung
infect
mice
barnard
et
al
evalu
prophylact
potenti
antivir
direct
sarscov
infect
new
lethal
anim
model
sar
need
facilit
antivir
research
adapt
character
new
strain
sarscov
strain
highli
lethal
balbc
mice
day
et
al
number
compound
test
efficaci
sarscovinfect
balbc
mice
day
et
al
use
adenoviru
vector
mous
interferonalpha
prophylact
treatment
therapeut
countermeasur
treat
lethal
sarscov
infect
balbc
mice
efficaci
protect
mice
death
kumaki
et
al
studi
treatment
interferon
induc
polyriboinosinicpolyribocytidyl
acid
stabil
polyllysin
carboxymethyl
cellulos
poli
ic
lc
given
intranas
rout
effect
protect
mice
lethal
infect
mouseadapt
sarscov
reduc
viral
lung
titer
kumaki
et
al
activ
immunomodul
poli
ic
lc
hiltonol
effect
therapi
initi
h
infect
late
h
viru
inocul
time
clinic
sign
sar
manifest
balbc
mice
report
evalu
use
hiltonol
extend
prophylact
therapeut
countermeasur
treat
lethal
sarscov
infect
balbc
mice
caus
mouseadapt
sarscov
addit
valu
vaccin
adjuv
assess
vero
cell
obtain
american
type
cultur
collect
atcc
manassa
va
routin
grown
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
thermo
fisher
scientif
co
logan
ut
vitro
antivir
assay
serum
reduc
fb
gentamicin
ad
medium
final
concentr
mgml
cov
strain
urbani
obtain
center
diseas
control
prevent
cdc
atlanta
ga
usa
strain
propag
titrat
vero
cell
mouseadapt
sarscov
strain
previous
describ
day
et
al
briefli
mice
infect
urbani
strain
three
five
day
infect
lung
remov
homogen
use
reinfect
subsequ
group
mice
infect
step
continu
time
balbc
mice
lung
viru
plaquepurifi
time
yield
viru
caus
sever
lung
diseas
mortal
infect
mice
viru
verifi
sarscov
enzymelink
immunosorb
assay
elisa
polymeras
chain
reaction
pcr
experi
involv
infecti
virus
conduct
approv
biosafeti
level
laboratori
interferon
induc
polyriboinosinicpolyribocytidyl
acid
stabil
polyllysin
carboxymethyl
cellulos
hiltonol
poli
ic
lc
obtain
andr
salazar
oncovir
inc
washington
dc
hiltonol
dilut
physiolog
steril
salin
pss
vivo
experi
use
ampligen
provid
hemispherx
biopharma
philadelphia
pa
specif
pathogenfre
femal
g
balbc
mice
obtain
charl
river
laboratori
wilmington
studi
mainli
femal
g
parent
strain
obtain
jackson
laboratori
bar
harbor
main
femal
g
parent
strain
mice
obtain
charl
river
laboratori
wilmington
maintain
wayn
lab
blox
fed
standard
mous
chow
tap
water
ad
libitum
mice
quarantin
h
prior
use
anim
studi
done
approv
biosafeti
level
anim
facil
personnel
enter
facil
wore
power
airpurifi
respir
hepa
airmat
saint
paul
mn
tyvek
bodi
protect
suit
anim
studi
approv
utah
state
univers
anim
care
committe
gener
experiment
design
describ
balbc
mice
anesthet
ml
intraperiton
inject
mgkg
ketamin
mouseadapt
sarscov
administ
intranas
volum
ml
group
mice
administ
hiltonol
vehicl
placebo
select
time
prior
challeng
pfu
mouseadapt
sarscov
ampligen
administ
h
viru
exposur
h
exposur
viru
serv
posit
control
control
viru
infect
fifteen
mice
treat
pss
variou
time
prior
viru
exposur
mice
group
repres
placebo
control
sarscovinfect
mockinfect
mice
weigh
everi
day
clinic
sign
diseas
also
observ
record
daili
anim
death
record
day
post
viru
exposur
follow
intranas
administr
sarscov
five
mice
group
sacrif
day
lung
score
lung
weight
lung
titer
determin
anim
lost
greater
initi
bodi
weight
human
euthan
co
asphyxi
day
euthan
design
day
death
due
infect
hiltonol
dose
rang
find
experi
carri
determin
maximum
toler
concentr
three
mice
use
per
treatment
group
toxic
evalu
term
weight
chang
advers
event
mice
weigh
everi
day
h
prior
viru
infect
day
post
viru
exposur
advers
event
observ
made
includ
ruffl
fur
lethargi
paralysi
incontin
repetit
circular
motion
aggress
sampl
mous
lung
lobe
weigh
place
petri
dish
lung
score
base
surfac
appear
lung
lung
assign
score
rang
indic
lung
look
normal
denot
entir
surfac
area
lung
inflam
exhibit
plum
color
lung
discolor
sidwel
et
al
signific
differ
lung
score
determin
kruskalw
test
follow
dunn
pairwis
comparison
post
test
oneway
analysi
varianc
anova
use
probe
signific
differ
lung
weight
pairwis
comparison
made
sidak
multipl
comparison
test
lung
viru
titer
analyz
mice
sacrif
day
post
viru
exposur
lobe
mous
lung
homogen
mem
supplement
fb
tissu
fragment
allow
settl
vari
dilut
supernat
fluid
assay
triplic
infecti
viru
vero
cell
cytopath
effect
cpe
assay
titer
tissu
cultur
infecti
dose
ccid
valu
calcul
use
reedmuench
method
reed
muench
signific
differ
detect
anova
pairwis
comparison
made
sidak
multipl
comparison
test
sera
harvest
submandibular
bleed
surviv
mice
day
viru
challeng
ml
aliquot
serum
sampl
ad
approxim
ml
mem
mix
serial
dilut
achiev
dilut
plate
viru
stock
dilut
mem
approxim
ccid
per
ml
next
ml
viru
ad
well
plate
vibrat
approxim
min
incub
h
c
neutral
ml
liquid
well
transfer
plate
contain
subconflu
monolay
vero
cell
ml
mem
fb
ad
well
plate
seal
tape
incub
day
c
co
score
presenc
absenc
viru
cytopath
effect
uninfect
well
serv
neg
cell
control
serum
sampl
known
antisar
antibodi
serv
posit
control
result
report
invers
greatest
dilut
viru
cpe
detect
group
mice
infect
describ
previous
sacrif
day
either
post
viru
exposur
lung
mockinfect
infect
mice
collect
formalinfix
lung
group
section
stain
h
e
stain
evalu
board
certifi
veterinari
pathologist
histopatholog
chang
mice
weigh
group
prior
treatment
everi
day
thereaft
determin
averag
weight
chang
anim
treatment
group
weight
express
group
averag
day
evalu
twoway
analysi
varianc
signific
differ
among
treatment
group
follow
pairwis
comparison
use
dunnett
multipl
comparison
test
surviv
analysi
done
use
kaplanmei
graphic
method
logrank
test
analysi
reveal
signific
differ
among
treatment
group
therefor
pairwis
comparison
survivor
curv
pss
versu
treatment
analyz
gehanbreslowwilcoxon
pairwis
comparison
test
rel
signific
adjust
bonferronicorrect
signific
threshold
number
treatment
comparison
done
mean
day
death
calcul
analyz
kruskalw
test
follow
dunn
post
test
evalu
signific
pairwis
comparison
live
number
per
total
mice
group
differ
evalu
conting
tabl
analysi
fisher
exact
test
use
make
pairwis
comparison
placebotr
mice
mice
randomli
assign
toxic
control
group
gain
weight
rate
nearli
equal
mice
receiv
pss
data
shown
mice
treat
hiltonol
mgkg
day
group
lose
notic
amount
weight
occur
day
howev
regain
lost
bodi
weight
nadir
weight
loss
day
mice
group
manag
rapidli
regain
lost
weight
end
experi
advers
event
observ
toxic
control
mice
use
experi
previou
studi
balbc
mice
inocul
intranas
mouseadapt
sarscov
infect
mice
die
day
mortal
rate
achiev
day
lung
sever
inflam
exhibit
extrem
lung
consolid
effici
viral
replic
observ
day
lung
day
et
al
viru
titer
often
exceed
ml
peak
replic
day
weight
loss
excess
current
studi
group
mice
administ
hiltonol
vehicl
placebo
select
time
prior
viru
challeng
mouseadapt
sarscov
mice
receiv
addit
dose
hiltonol
viru
challeng
dose
treatment
regimen
hiltonol
significantli
protect
mice
lethal
infect
balbc
mice
expos
sarscov
fig
p
tabl
three
mice
die
use
hiltonol
one
mous
day
post
viru
exposur
dose
mgkgday
h
infect
one
mous
day
receiv
hiltonol
mgkgday
dose
given
h
infect
one
mous
day
treat
three
time
lower
dose
hiltonol
mgkgday
h
infect
treat
sarscovinfect
mice
receiv
variou
hiltonol
dose
regimen
also
significantli
protect
weight
loss
due
viru
infect
tabl
p
day
post
viru
exposur
greatest
weight
loss
occur
mous
model
also
evalu
far
initi
viru
challeng
time
prophylact
dose
regimen
would
efficaci
protect
mice
lethal
challeng
sarscov
group
mice
dose
hiltonol
mgkg
intranas
instil
day
viru
exposur
second
dose
given
h
later
hiltonol
administ
mgkgday
begin
day
viru
exposur
protect
infect
mice
death
due
viru
infect
fig
p
hiltonol
dose
regimen
protect
administ
mgkg
one
time
day
prior
expos
mice
viru
ampligen
use
mg
kg
significantli
p
yet
protect
mice
death
use
design
therapeut
treatment
regimen
critic
time
day
post
viru
exposur
mani
mice
began
die
placebo
treat
group
mice
treat
hiltonol
mgkg
day
infect
seem
least
suscept
weight
loss
due
viru
infect
compar
correspond
placebo
control
data
shown
placebotr
mice
usual
die
day
tabl
wherea
mice
treat
higher
dose
hiltonol
surviv
signific
number
p
also
obviou
mice
treat
lower
dose
hiltonol
surviv
signific
number
provid
hiltonol
administ
day
viru
infect
administ
mgkgday
day
viru
infect
almost
treat
mice
hiltonol
group
die
mean
day
death
equival
correspond
placebo
control
group
tabl
ampligen
given
ip
twice
day
begin
h
infect
mgkg
mice
receiv
ampligen
slightli
yet
significantli
protect
death
survivor
tabl
p
effect
hiltonol
lung
score
lung
weight
viru
lung
titer
femal
balbc
mice
infect
lethal
dose
mouseadapt
sarscov
day
post
viru
exposur
paramet
measur
determin
extent
efficaci
two
prophylact
dose
hiltonol
includ
effect
gross
lung
patholog
lung
weight
viru
lung
titer
day
mice
expos
viru
mgkg
dose
hiltonol
significantli
amelior
extent
damag
induc
viru
infect
observ
surfac
lung
infect
mice
p
tabl
littl
surfac
hemorrhag
observ
addit
almost
mice
treat
dose
hiltonol
regardless
time
administr
protect
extent
tabl
treatment
lower
dose
hiltonol
led
similar
result
less
observ
surfac
lung
patholog
especi
mice
treat
hiltonol
begin
day
viru
exposur
p
anoth
indic
extent
inflammatori
respons
lung
edema
edema
indirectli
measur
evalu
weight
infect
lung
day
viru
infect
dose
mgkg
hiltonol
use
treatment
regimen
significantli
prevent
increas
lung
weight
treat
mice
manifest
edema
tabl
p
howev
efficaci
repress
edema
much
less
pronounc
mice
receiv
mgkg
dose
hiltonol
ampligen
treatment
result
similar
efficaci
profil
prevent
edema
seen
mice
dose
hiltonol
mgkg
appar
moder
inflammatori
respons
lung
surfac
lung
due
correl
reduct
viru
replic
lung
infect
mice
presenc
viru
protein
like
culprit
induc
edema
gener
viru
lung
titer
day
inocul
viru
almost
log
lower
mice
treat
mgkg
hiltonol
compar
placebotr
control
tabl
howev
viru
lung
titer
mice
b
fig
effect
hiltonol
surviv
balbc
mice
lethal
sarscov
infect
p
versu
pss
sarscovinfect
balbc
mice
treat
pss
c
h
h
h
hiltonol
mgkgday
h
b
h
hiltonol
mgkgday
h
h
h
h
h
h
h
h
h
h
b
effect
variou
longterm
dose
regimen
hiltonol
surviv
balbc
mice
lethal
sarscov
infect
p
versu
pss
sarscovinfect
balbc
mice
treat
pss
c
day
b
day
day
hiltonol
mgkg
day
mgkgday
mgkgday
mgkg
day
mgkgday
mgkgday
second
dose
given
h
later
ampligen
mgkgday
bid
x
beg
h
treat
mgkg
hiltonol
day
infect
significantli
reduc
compar
viru
titer
mice
receiv
pss
reduc
almost
one
compar
placebo
treat
mice
tabl
none
treatment
includ
ampligen
achiev
reduct
viru
lung
titer
effect
variou
longterm
dose
regimen
hiltonol
neutral
antibodi
titer
balbc
mice
day
post
challeng
lethal
dose
sarscov
conceiv
immun
modul
interferon
induc
could
suppress
normal
adapt
immun
respons
format
neutral
antibodi
effect
hiltonol
treatment
immun
respons
also
investig
analyz
neutral
antibodi
level
viru
day
viru
challeng
sera
group
mice
use
long
term
prophylaxi
experi
analyz
neutral
antibodi
fig
b
data
suggest
mice
treat
high
dose
hiltonol
could
still
mount
robust
viru
neutral
respons
even
though
drug
significantli
reduc
viru
lung
titer
one
case
fact
mice
receiv
pretreat
hiltonol
begin
day
day
viru
challeng
signific
higher
neutral
antibodi
titer
correspond
placebotr
mice
fig
p
p
respect
neutral
antibodi
titer
remain
equival
high
higher
day
post
tabl
effect
variou
dose
regimen
hiltonol
lethal
sarscov
infect
balbc
mous
model
livetot
mean
day
death
sd
weight
loss
day
day
g
averag
weight
day
g
sd
pss
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
p
p
p
effect
variou
longterm
dose
regimen
hiltonol
surviv
balbc
mice
lethal
sarscov
infect
dose
regimen
day
prior
viru
exposur
survivorstot
mean
day
death
sd
pss
hiltonol
mgkgday
hiltonol
mgkgday
pss
hiltonol
mgkgday
hiltonol
mgkgday
pss
hiltonol
mgkgday
hiltonol
mgkgday
ampligen
mgkgday
bid
x
beg
h
p
p
compar
pss
control
viru
challeng
fig
interestingli
group
mice
receiv
lowest
dose
hiltonol
appear
higher
neutral
antibodi
titer
day
day
one
could
specul
observ
driven
fact
viru
titer
higher
mice
treatment
mice
low
dose
hiltonol
ampligen
also
show
similar
result
would
suggest
dose
hiltonol
advers
affect
adapt
immun
respons
gener
lung
infect
sarscov
show
acut
subacut
alveol
perivascular
edema
section
lung
mice
inocul
sarscov
show
signific
chang
mockinfect
control
show
mark
chang
except
moder
rim
lymphocyt
surround
scatter
vessel
fig
also
patholog
chang
observ
sarscovinfect
hiltonol
treat
lung
fig
howev
signific
patholog
differ
distribut
inflammatori
cell
sarscovinfect
mockinfect
lung
observ
three
sarscovinfect
hiltonol
treat
lung
sampl
mgkg
day
viru
exposur
evalu
patholog
chang
day
inocul
ampligen
treat
mice
posit
controltr
group
infect
limit
littl
evid
inflammatori
respons
lung
mous
observ
although
tremend
amount
erythrocyt
infiltr
air
space
fig
efficaci
hiltonol
mgkgday
treatment
sarscov
infect
evalu
hiltonol
h
post
viru
challeng
surviv
weight
monitor
daili
least
day
hiltonol
given
mgkgday
result
surviv
treat
infect
mice
administ
h
post
viru
challeng
time
clinic
sign
sar
start
manifest
untreat
balbc
mice
p
tabl
addit
treatment
hiltonol
mgkgday
intranas
rout
result
surviv
given
twice
h
post
viru
exposur
tabl
p
data
suggest
hiltonol
treatment
sarscov
infect
mice
lead
substanti
therapeut
effect
protect
mice
death
administ
within
h
viru
exposur
use
therapeut
multipl
dose
regimen
hiltonol
given
one
time
mgkgday
protect
death
treatment
h
sarscov
infect
tabl
hiltonol
administ
intranas
h
post
viru
challeng
data
show
partial
surviv
tabl
anoth
subsequ
therapeut
experi
hiltonol
administ
intranas
h
post
viru
exposur
day
mice
receiv
hiltonol
h
exposur
viru
still
aliv
compar
therapeut
regimen
dead
one
mous
surviv
data
shown
data
suggest
treatment
begin
h
viru
exposur
might
temporarili
prolong
surviv
pathogenesi
caus
viru
final
overwhelm
mice
interleukin
multifunct
cytokin
regul
immun
respons
hematopoiesi
acut
phase
respons
inflamm
hirano
previous
report
level
increas
sarscovinfect
mice
high
express
associ
mortal
day
et
al
therefor
evalu
effect
viru
infect
mice
defici
sinc
mutant
mice
show
defect
respons
variou
virus
inflammatori
respons
infect
hypothes
mortal
diseas
paramet
might
reduc
mice
infect
sarscov
increas
level
contribut
greatli
lethal
infect
normal
mice
day
et
al
b
fig
effect
variou
longterm
dose
regimen
hiltonol
neutral
antibodi
titer
balbc
mice
day
b
post
viru
challeng
lethal
dose
sarscov
p
versu
pss
day
p
versu
hiltonol
mgkg
day
hiltonol
mgkg
day
sarscovinfect
balbc
mice
treat
pss
c
day
b
day
day
hiltonol
mgkgday
mgkgday
mgkgday
mg
kgday
mgkgday
mgkgday
ampligen
mgkgday
bid
x
beg
h
hypothesi
assum
product
major
sourc
lung
diseas
sarscovinfect
mice
sarscovinfect
mice
treat
hiltonol
mgkgday
typic
depress
weight
gain
hiltonol
treatment
observ
day
although
significantli
sever
mice
data
shown
howev
surviv
mice
gain
back
lost
weight
end
experi
hiltonol
significantli
protect
mice
death
either
strain
mous
compar
placebotr
mice
strain
tabl
mice
still
support
viru
lung
replic
addit
mean
day
death
group
howev
viru
lung
titer
mice
significantli
reduc
day
post
viru
exposur
tabl
p
effect
variou
longterm
dose
regimen
hiltonol
death
balbc
mice
infect
lethal
dose
sarscov
post
viru
exposur
dose
regimen
hour
post
viru
exposur
livetot
mean
day
death
pss
h
hiltonol
mgkgday
h
undefin
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
hiltonol
mgkgday
h
undefin
hiltonol
mgkgday
h
undefin
p
versu
pss
control
mice
significantli
highli
viru
titer
normal
mice
tabl
p
suggest
necessari
control
viru
replic
lung
interestingli
day
hiltonol
treat
mice
significantli
increas
viru
lung
titer
compar
untreat
infect
mice
tabl
p
addit
viru
infect
lung
like
induc
signific
yet
slight
inflammatori
respons
untreat
infect
mice
p
measur
increas
lung
score
induct
edema
mice
seen
normal
lung
weight
tabl
inabl
significantli
control
viru
replic
may
one
reason
mice
protect
death
thu
viru
cytopath
effect
may
suffici
destroy
enough
lung
cell
contribut
poor
lung
function
may
lead
death
mice
succumb
viru
infect
data
suggest
mice
mice
mice
lack
pathway
hiltonol
interact
prevent
lethal
sarscov
infect
mice
khanolkar
et
al
report
mice
harbor
natur
mutat
gene
encod
tolllik
receptor
disrupt
normal
function
exhibit
enhanc
morbid
mortal
follow
mous
hepat
viru
strain
infect
indic
play
import
role
respiratori
cov
pathogenesi
khanolkar
et
al
current
studi
hypothes
intranas
infect
mice
mouseadapt
sarscov
would
result
acut
respiratori
diseas
higher
lethal
strain
mice
infect
sarscov
treat
hiltonol
infect
untreat
mice
lost
weight
onset
weight
loss
delay
rel
hiltonol
infect
mice
data
shown
except
one
mous
die
day
post
viru
exposur
despit
induc
death
strain
mice
viru
abl
replic
quit
rigor
lung
mice
tabl
previous
seen
mice
tabl
yet
viru
induc
signific
inflammatori
respons
manifest
lack
increas
lung
score
lack
induct
edema
manifest
normal
lung
weight
tabl
nevertheless
viru
lung
titer
dramat
reduc
strain
mice
treat
hiltonol
p
mice
especi
day
addit
mice
less
suitabl
host
prolong
lung
viru
replic
mice
viru
lung
titer
day
mice
significantli
lower
mice
p
data
indic
hiltonol
action
appear
independ
locu
host
innat
immun
respons
viral
insult
includ
product
interferon
type
ifnab
initi
limit
viral
replic
virusinfect
cell
usual
caus
activ
sever
transcript
factor
interferon
regulatori
factor
play
central
role
downstream
gene
activ
lin
et
al
interferon
synthes
secret
cell
bind
cell
surfac
receptor
induc
transcript
result
antivir
state
target
cell
epitheli
cell
secret
interferonb
initi
respons
viral
infect
mari
et
al
dendrit
cell
abl
produc
infa
subtyp
diebold
et
al
howev
product
interferon
type
sarscovinfect
cell
limit
chen
subbarao
spiegel
et
al
neither
endogen
interferon
transcript
interferon
promot
activ
detect
spiegel
et
al
lack
interferon
activ
attribut
protein
antagon
interferon
block
transcript
factor
necessari
express
interferon
kopeckybromberg
et
al
although
sarscov
antagon
product
effect
endogen
interferon
remain
suscept
exogen
interferon
chen
subbarao
kumaki
et
al
interferon
induct
occur
mainli
intracellular
pathway
doublestrand
ds
rna
singlestrand
ss
rna
trigger
signal
chain
activ
interferonb
gene
express
hornung
et
al
pichlmair
et
al
weber
et
al
retinoicacidinduc
gene
rigi
tabl
effect
hiltonol
death
mice
infect
lethal
dose
mouseadapt
sarscov
dose
regimen
hour
post
viru
exposur
livetot
mean
day
death
pss
h
hiltonol
h
pss
h
hiltonol
h
p
versu
pss
control
effect
hiltonol
variou
lung
paramet
measur
knockout
mice
mice
infect
mous
adapt
sarscov
viru
titer
log
ccid
g
sd
visual
lung
score
sd
lung
weight
g
sd
day
pss
hiltonol
mgkg
pss
hiltonol
mgkg
day
pss
hiltonol
mgkg
pss
hiltonol
mgkg
p
versu
pss
control
melanomadifferentiationassoci
gene
main
intracellular
receptor
viral
rna
andrejeva
et
al
kato
et
al
yoneyama
et
al
bind
viral
rna
rigi
induc
signal
chain
result
phosphoryl
transcript
factor
fitzgerald
et
al
sharma
et
al
synthetas
oa
silverman
protein
kinas
r
pkr
william
also
character
detail
oa
catalys
synthesi
short
oligoadenyl
activ
latent
endoribonucleas
silverman
pkr
serinethreonin
kinas
phosphoryl
alpha
subunit
eukaryot
translat
initi
factor
william
addit
interferon
induct
also
occur
endosom
pathway
select
cell
myeloid
dendrit
cell
mdc
diebold
et
al
plasmacytoid
dendrit
cell
pdc
colonna
et
al
main
interferon
produc
lymphat
system
myeloid
dendrit
cell
mdc
senc
dsrna
classic
intracellular
pathway
diebold
et
al
endosom
tolllik
receptor
tlr
alexopoul
et
al
recogn
viral
ssrna
dsrna
respect
activ
interferonab
transcript
via
transcript
factor
nfkb
pathogenesi
sever
acut
respiratori
syndrom
yet
fulli
character
one
hypothesi
pathogenesi
sarscov
caus
disproportion
immun
respons
illustr
elev
level
inflammatori
cytokin
chemokin
interferon
gamma
induc
protein
monocyt
chemoattract
interleukin
interleukin
jiang
et
al
wong
et
al
chemokin
involv
recruit
leukocyt
site
tissu
inflamm
sauti
et
al
sarscov
shown
vitro
induc
chang
cytokin
chemokin
variou
human
anim
cell
spiegel
weber
yen
et
al
monomor
amino
acid
secret
tcell
macrophag
endotheli
cell
stimul
immun
respons
infect
ray
et
al
sehgal
et
al
sehgal
et
al
xiao
et
al
specul
dampen
proinflammatori
cytokin
respons
sarscov
infect
particular
product
could
clinic
benefici
effect
xiao
et
al
notic
sarscov
infect
increas
mice
high
express
correct
mortal
day
et
al
level
drop
balbc
mice
treat
ribavirin
uda
mgkgday
ampligen
hiltonol
mgkg
day
day
et
al
kumaki
et
al
cytokin
releas
apic
basolater
side
secret
apic
surfac
yoshikawa
et
al
specul
sar
patient
might
directli
produc
virusinfect
cell
wherea
upregul
like
secondari
respons
due
activ
immun
system
addit
trif
pathway
lead
product
type
interferon
via
interferon
regulatori
factor
also
caus
delay
nfkb
activ
via
activ
tnf
receptorassoci
factor
hoeb
et
al
sato
et
al
imai
et
al
also
show
trifdepend
lung
injuri
like
mediat
product
interleukin
mice
protect
injuri
imai
et
al
tolllik
receptor
tlr
famili
evolutionarili
conserv
pathogen
recognit
receptor
class
protein
play
key
role
innat
immun
system
tlr
famili
consist
mammalian
member
viral
protein
bind
singl
strand
rna
bind
doubl
strand
rna
bind
viral
dna
bind
recogn
viral
nucleic
acid
endosom
membran
bind
ligand
tlr
might
trigger
downstream
signal
pathway
involv
cytokin
releas
primari
induct
inflamm
secondari
activ
antiinflammatori
mechan
netea
et
al
tlr
intrins
signal
pathway
induc
specif
biolog
respons
microorgan
dendrit
cell
matur
cytokin
product
develop
adapt
immun
murawski
et
al
recogn
viral
protein
fusion
f
protein
respiratori
syncyti
viru
envelop
protein
mous
mammari
tumor
viru
uematsu
akira
mice
sensit
respiratori
syncyti
viru
infect
murawski
et
al
trigger
induct
proinflammatori
cytokin
myeloid
differenti
primari
respons
gene
pathway
also
interact
tirdomaincontain
adapterinduc
interferonb
trif
mediat
signal
pathway
involv
interferon
induct
uematsu
akira
mechan
action
behind
encourag
result
remain
elucid
hiltonol
poli
ic
lc
polyinosinicpolycytidyl
acid
stabil
polylysin
carboxymethylcellulos
chemic
stabil
activ
doublestrand
rna
dsrna
therapeut
activ
host
innat
adapt
immun
variou
pathwaysmechan
lead
induct
immedi
antivir
state
immedi
antivir
state
character
induct
natur
mix
interferon
cytokin
chemokin
activ
dsrnadepend
host
defens
system
rigi
oa
pkr
stimul
mdc
natur
killer
nk
cell
other
via
tolllik
receptor
tolllik
receptor
also
implic
lung
airway
injuri
well
lead
benefici
respons
antigen
insult
imai
et
al
demonstr
acut
lung
injuri
ali
trigger
signal
oxid
stress
tolllik
receptor
imai
et
al
khanolkar
et
al
report
mice
harbor
natur
mutat
gene
encod
tolllik
receptor
disrupt
normal
function
exhibit
enhanc
morbid
mortal
follow
mous
hepat
viru
strain
tabl
effect
hiltonol
variou
lung
paramet
mice
mice
infect
lethal
dose
mouseadapt
sarscov
viru
titer
log
ccid
g
sd
visual
lung
score
sd
lung
weight
g
sd
day
pss
mice
hiltonol
mgkg
mice
pss
mice
hiltonol
mgkg
mice
day
pss
mice
hiltonol
mgkg
mice
pss
mice
hiltonol
mgkg
mice
p
versu
pss
control
infect
indic
play
import
role
respiratori
cov
pathogenesi
khanolkar
et
al
studi
hypothes
whether
intranas
infect
mice
mouseadapt
sarscov
would
result
acut
respiratori
diseas
higher
lethal
howev
data
present
consist
hypothesi
tolllik
receptor
member
tolllik
receptor
famili
pattern
recognit
receptor
innat
immun
system
rock
et
al
express
respiratori
epithelium
well
mdc
especi
respons
respiratori
infect
influenza
use
mice
gowen
et
al
indic
play
import
role
punta
toro
viru
ptv
infect
gowen
et
al
ichinoh
et
al
also
demonstr
even
earlier
activ
lung
respons
nasal
hiltonol
polyic
mice
ichinoh
et
al
host
defens
mechan
typic
activ
present
foreign
dsrna
speci
gener
viral
replic
mani
also
frequent
target
inhibit
mani
neoplasm
virus
includ
influenza
viru
sarscov
treatment
mucos
appli
hiltonol
may
preempt
revers
viral
evas
mechan
appar
modul
hiltonol
usual
relationship
host
surviv
replic
sarscov
manifest
clinic
protect
anim
spite
evid
viral
replic
also
much
interest
exampl
complet
inhibit
viral
replic
might
counterproduct
gener
longer
term
adapt
immun
thu
dsrna
depend
antiviralantiprolif
pathway
mention
may
help
control
replic
potenti
activ
mdc
via
hiltonol
seen
improv
effici
antigen
present
may
particularli
suit
gener
cellular
antivir
immun
fact
tlr
propos
bridg
innat
adapt
immun
remain
determin
whether
involv
sarscov
infect
mice
hiltonol
extens
preclin
experiment
clinic
therapeut
use
evid
clinic
safeti
potent
antivir
immun
adjuv
antineoplast
action
alon
combin
agent
levi
et
al
initi
highdos
studi
quasiempir
driven
induct
interferon
yet
recent
effect
lower
dose
broad
mechan
action
begun
fulli
elucid
extens
earli
empir
experi
broad
vivo
antivir
action
hiltonol
yet
action
fulli
exploit
context
prophylaxi
emerg
infect
pandem
contain
biodefens
mucos
intranas
hiltonol
provid
rapid
complet
protect
respiratori
virus
influenza
viru
sarscov
rsv
guerreroplata
et
al
kumaki
et
al
wong
et
al
wong
et
al
wong
et
al
demonstr
protect
last
week
provid
intranas
aqueou
liposom
hiltonol
otherwis
lethal
murin
challeng
model
influenza
avian
influenza
virus
hiltonol
shown
efficaci
yellow
fever
simian
hemorrhag
fever
levi
et
al
japanes
enceph
harrington
et
al
rabi
baer
et
al
rift
valley
fever
kend
et
al
antivir
activ
hiltonol
believ
mediat
abil
augment
product
interferona
b
g
levi
et
al
hiltonol
also
activ
natur
killer
cell
macrophag
antivir
efficaci
hiltonol
previous
evalu
avian
influenza
viru
hiltonol
appear
provid
effect
broadspectrum
prophylaxi
avian
influenza
viru
wong
et
al
vivo
studi
recommend
administ
safe
dose
hiltonol
mgkg
day
pilot
trial
salazar
et
al
report
low
dose
hiltonol
mcgkg
given
intramuscularli
two
three
time
weekli
month
malign
brain
tumor
patient
salazar
et
al
patient
toler
regimen
well
littl
toxic
preserv
qualiti
life
conclud
concept
longterm
broad
spectrum
stimul
host
defens
nontox
inexpens
doublestrand
ribonucl
acid
hiltonol
mcgkg
might
applic
treatment
viru
infect
current
studi
data
suggest
nasal
hiltonol
treatment
sarscov
infect
mice
lead
substanti
longterm
prophylact
somewhat
less
robust
therapeut
effect
protect
mice
death
weight
loss
result
infect
hosttarget
therapeut
hiltonol
activ
innat
immun
provid
immedi
broad
spectrum
resist
could
fill
earli
gap
protect
allow
time
specif
vaccin
strategi
take
effect
could
thu
becom
import
element
rapid
respons
bioterror
attack
pandem
outbreak
hiltonol
repres
rel
new
hostdirect
paradigm
therapeut
seek
activ
nonspecif
specif
host
defens
system
highli
evolv
million
year
hiltonol
also
potenti
use
prophylact
potenti
expos
sarscov
yet
show
symptom
thu
enabl
clinician
ring
isol
focu
case
individu
prophylact
treat
unlik
get
sever
diseas
unlik
get
diseas
demonstr
clinic
safeti
hiltonol
immedi
induct
innat
immun
persist
broad
spectrum
antivir
state
rel
low
cost
stabil
storag
rel
eas
use
make
potenti
valuabl
agent
contain
epidem
caus
respiratori
pathogen
hiltonol
broad
spectrum
antivir
activ
also
repres
potenti
therapi
merscov
infect
well
sinc
merscov
relat
coronaviru
caus
sever
respiratori
infect
dose
sarscov
